trial

Efficacy, Safety, and Tolerability of TC-5619 as Augmentation Therapy to Improve Negative Symptoms and Cognition in Outpatients With Schizophrenia

NCTId NCT01488929
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 603 (actual)
Sponsored by Targacept Inc.
Primary completion 2013-11
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
603 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2011-12
Primary completion
2013-11
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
TC-5619

Sponsors

Targacept Inc.Lead Sponsor

Investigators

1
David P Walling, PhDPrincipal Investigator

Sites

64 total
Garden Grove, United StatesGlendale, United StatesLong Beach, United StatesNational City, United StatesOceanside, United StatesOrange, United StatesSan Diego, United StatesLauderhill, United StatesLeesburg, United StatesAtlanta, United StatesHoffman Estates, United StatesFlowood, United States

Linked catalysts

1
Efficacy, Safety, and Tolerability of TC-5619 as Augmentation Therapy to Improve — primary completion2013-11

Facts & assertions

4 sourced
Enrollment
603
Phase
PHASE2
Primary Completion Date
2013-11
Status
COMPLETED
relationships
The graph out of here
drug
TC-5619
drug
lead_sponsor
Targacept Inc.
company
indication
Negative Symptoms
indication
Cognitive Dysfunction
indication
Schizophrenia
indication
investigator
David P Walling, PhD
person